Taysha Gene Therapies (TSHA) Scheduled to Post Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is scheduled to release its earnings data after the market closes on Wednesday, November 13th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The firm had revenue of $1.11 million for the quarter, compared to analyst estimates of $3.62 million. During the same period last year, the firm posted ($0.38) earnings per share. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $1.42 on Thursday. The business has a 50 day moving average of $2.02 and a 200-day moving average of $2.42. The company has a market capitalization of $291.02 million, a P/E ratio of -6.85 and a beta of 0.44. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TSHA. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Canaccord Genuity Group decreased their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, Needham & Company LLC lowered their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $6.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.